Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.34 |
| ▸ | ESR1 | P03372 | 7/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.32 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13970074 | 0.84 | KDM1A (0.35) | KDM1AESR2ESR1SENP1HSD17B1 | |
| SCHEMBL3687905 | 0.83 | ESR1 (0.34) | KDM1AESR2ESR1 | |
| SCHEMBL3684902 | 0.77 | ESR2 (0.36) | KDM1AESR2ESR1SENP1HSD17B1 | |
| SCHEMBL3640476 | 0.77 | ESR2 (0.38) | KDM1AESR2ESR1SENP1HSD17B1 | |
| SCHEMBL3676121 | 0.77 | ESR2 (0.36) | KDM1AESR2ESR1SENP1HSD17B1 | |
| SCHEMBL13261938 | 0.75 | ESR1 (0.33) | KDM1AESR2ESR1SENP1 | |
| SCHEMBL3642379 | 0.75 | ESR1 (0.33) | KDM1AESR2ESR1SENP1 | |
| SCHEMBL13261939 | 0.75 | ESR1 (0.33) | KDM1AESR2ESR1SENP1 | |
| SCHEMBL3644644 | 0.74 | CYP19A1 (0.32) | ESR2ESR1 | |
| SCHEMBL13970045 | 0.69 | KDM1A (0.36) | KDM1AESR2ESR1SENP1DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | claimed |
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
| EP-2176209-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009012954-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, ESR2 | KDM1A 737/4885ESR2 3/4885ESR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.